Deutsche Bank flags triple upside for psychedelic drug developer as therapy boom grows
TL;DR
Deutsche Bank analysts anticipate a leading psychedelic-drug developer could triple its stock as psychedelic therapies gain mainstream traction, signaling significant upside for investors in this biotech niche.
Want the full story? Read the original reporting
Read on cnbc.com